AstraZeneca Bladder Cancer Treatment Reduced Recurrence Risk 49%

Perioperative Imfinzi plus neoadjuvant enfortumab vedotin reduced recurrence risk by 49% and risk of death by 42% in muscle-invasive bladder cancer.